Compare Natco Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA CADILA HEALTHCARE NATCO PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 15.5 14.4 108.0% View Chart
P/BV x 3.0 2.8 108.7% View Chart
Dividend Yield % 1.5 1.5 100.1%  

Financials

 NATCO PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
CADILA HEALTHCARE
Mar-18
NATCO PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,080558 193.5%   
Low Rs671362 185.7%   
Sales per share (Unadj.) Rs592.1116.3 509.2%  
Earnings per share (Unadj.) Rs188.417.9 1,054.4%  
Cash flow per share (Unadj.) Rs206.323.1 892.1%  
Dividends per share (Unadj.) Rs8.253.50 235.7%  
Dividend yield (eoy) %0.90.8 123.8%  
Book value per share (Unadj.) Rs833.685.4 975.9%  
Shares outstanding (eoy) m36.901,023.74 3.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.54.0 37.4%   
Avg P/E ratio x4.625.7 18.1%  
P/CF ratio (eoy) x4.219.9 21.4%  
Price / Book Value ratio x1.15.4 19.5%  
Dividend payout %4.419.6 22.4%   
Avg Mkt Cap Rs m32,311470,664 6.9%   
No. of employees `0004.811.8 40.9%   
Total wages/salary Rs m3,25618,545 17.6%   
Avg. sales/employee Rs Th4,522.510,072.7 44.9%   
Avg. wages/employee Rs Th674.01,569.1 43.0%   
Avg. net profit/employee Rs Th1,439.01,547.7 93.0%   
INCOME DATA
Net Sales Rs m21,848119,049 18.4%  
Other income Rs m4041,132 35.7%   
Total revenues Rs m22,252120,181 18.5%   
Gross profit Rs m9,28428,475 32.6%  
Depreciation Rs m6625,388 12.3%   
Interest Rs m154911 16.9%   
Profit before tax Rs m8,87223,308 38.1%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,9205,644 34.0%   
Profit after tax Rs m6,95218,292 38.0%  
Gross profit margin %42.523.9 177.7%  
Effective tax rate %21.624.2 89.4%   
Net profit margin %31.815.4 207.1%  
BALANCE SHEET DATA
Current assets Rs m21,30782,005 26.0%   
Current liabilities Rs m5,92060,720 9.7%   
Net working cap to sales %70.417.9 393.9%  
Current ratio x3.61.4 266.5%  
Inventory Days Days7373 100.1%  
Debtors Days Days10798 108.3%  
Net fixed assets Rs m14,98683,703 17.9%   
Share capital Rs m3691,024 36.0%   
"Free" reserves Rs m30,35386,421 35.1%   
Net worth Rs m30,76087,445 35.2%   
Long term debt Rs m025,551 0.0%   
Total assets Rs m37,151180,653 20.6%  
Interest coverage x58.626.6 220.5%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.7 89.2%   
Return on assets %19.110.6 179.9%  
Return on equity %22.620.9 108.0%  
Return on capital %29.322.0 133.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,32242,683 24.2%   
Fx outflow Rs m2,97811,242 26.5%   
Net fx Rs m7,34331,441 23.4%   
CASH FLOW
From Operations Rs m4,6369,193 50.4%  
From Investments Rs m-11,155-9,737 114.6%  
From Financial Activity Rs m6,509515 1,263.9%  
Net Cashflow Rs m-18-29 62.1%  

Share Holding

Indian Promoters % 52.0 74.8 69.6%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 8.3 94.5%  
FIIs % 16.6 5.9 281.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 11.0 236.4%  
Shareholders   25,395 44,069 57.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SUVEN LIFESCIENCES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 17, 2019 02:29 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS